Sirolimus interferes with iron homeostasis in renal transplant recipients

被引:65
|
作者
Maiorano, Annamaria
Stallone, Giovanni
Schena, Antonio
Infante, Barbara
Pontrelli, Paola
Schena, Francesco Paolo
Grandaliano, Giuseppe
机构
[1] Univ Bari, Div Nephrol, Dept Emergency & Transplantat, I-70124 Bari, Italy
[2] Univ Foggia, Div Nephrol, Dept Biomed Sci, Foggia, Italy
关键词
sirolimus; anemia; renal transplantation; hepcidin;
D O I
10.1097/01.tp.0000235545.49391.1b
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Sirolimus is an immunosuppressive drug whose use is frequently associated with anemia. A pathogenic link between sirolimus-induced anemia and the appearance of an inflammatory state was recently suggested. Because inflammation-related anemia is characterized by a functional iron deficiency, we investigated whether sirolimus may influence iron homeostasis and serum levels of hepcidin, a key mediator of inflammation-related-anemia. Methods. To this purpose, 42 consecutive transplanted patients with biopsy-proven chronic allograft nephropathy were randomized (2:1 ratio) to receive either a 40% cyclosporine reduction (group A, 14 patients) or immediate cyclosporine withdrawal and sirolimus introduction (group B, 28 patients). Hemoglobin levels and iron status were evaluated 6 months before and after randomization. Results. The two groups had similar hemoglobin levels and iron status at baseline. We did not observe any significant change in hemoglobin and iron status in group A patients after randomization. On the contrary, we observed a significant reduction of hemoglobin without any change of red blood cell count after sirolimus introduction, with a significant reduction of mean corpuscular volume and mean corpuscular hemoglobin. Serum iron and transferrin saturation (TSAT) levels were markedly reduced after the switch, while ferritin serum concentrations remained stable. Although sirolimus-induced anemia was recently suggested to resemble inflammation-related anemia, hepcidin serum levels were similar in the two groups after randomization. None of group A and eight of group B patients presented a TSAT < 20 and were given iron supplementation after randomization, in all of them oral iron therapy did not influence either hemoglobin or serum iron levels. Conclusion. We demonstrated that sirolimus-induced anemia is independent of the drug antiproliferative effect and does not present the features of inflammation-related anemia. This event maybe due to the direct influence of sirolimus on iron homeostasis.
引用
收藏
页码:908 / 912
页数:5
相关论文
共 50 条
  • [1] Angioedema in renal transplant recipients on sirolimus
    Mahe, Emmanuel
    Morelon, Emmanuel
    Lechaton, Sophie
    Kreis, Henri
    de Prost, Yves
    Bodemer, Christine
    DERMATOLOGY, 2007, 214 (03) : 205 - 209
  • [2] Sirolimus in renal transplant recipients with malignancies in Germany
    Naik, Marcel G.
    Arns, Wolfgang
    Budde, Klemens
    Diekmann, Fritz
    Eitner, Frank
    Gwinner, Wilfried
    Heyne, Nils
    Jurgensen, Jan Steffen
    Morath, Christian
    Riester, Udo
    Heller, Katharina M.
    Fischereder, Michael
    CLINICAL KIDNEY JOURNAL, 2021, 14 (09) : 2047 - 2058
  • [3] Linear growth in pediatric renal transplant recipients receiving sirolimus
    Hymes, Leonard C.
    Warshaw, Barry L.
    PEDIATRIC TRANSPLANTATION, 2011, 15 (06) : 570 - 572
  • [4] Factors associated with proteinuria in renal transplant recipients treated with sirolimus
    Liew, Adrian
    Chiang, Gilbert S. C.
    Vathsala, Anantharaman
    TRANSPLANT INTERNATIONAL, 2009, 22 (03) : 313 - 322
  • [5] Sirolimus may reduce fertility in male renal transplant recipients
    Zuber, J.
    Anglicheau, D.
    Elie, C.
    Bererhi, L.
    Timsit, M-O.
    Mamzer-Bruneel, M-F.
    Ciroldi, M.
    Martinez, F.
    Snanoudj, R.
    Hiesse, C.
    Kreis, H.
    Eustache, F.
    Laborde, K.
    Thervet, E.
    Legendre, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (07) : 1471 - 1479
  • [6] Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients
    van den Akker, J. M.
    Wetzels, J. F. M.
    Hoitsma, A. J.
    KIDNEY INTERNATIONAL, 2006, 70 (07) : 1355 - 1357
  • [7] The effect of sirolimus on sex hormone levels of male renal transplant recipients
    Lee, S
    Coco, M
    Greenstein, SM
    Schechner, RS
    Tellis, VA
    Glicklich, DG
    CLINICAL TRANSPLANTATION, 2005, 19 (02) : 162 - 167
  • [8] Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients
    Morales, JM
    Wramner, L
    Kreis, H
    Durand, D
    Campistol, JM
    Burke, JT
    Groth, CG
    AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (05) : 436 - 442
  • [9] Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients
    Pescovitz, MD
    Govani, M
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S16 - S21
  • [10] Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus
    Backman, L
    Reisæter, AV
    Wramner, L
    Ericzon, BG
    Salmela, K
    Brattström, C
    CLINICAL TRANSPLANTATION, 2006, 20 (03) : 336 - 339